Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

Interest Coverage 1.50
CRTX's Interest Coverage is ranked lower than
95% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CRTX: 1.50 )
Ranked among companies with meaningful Interest Coverage only.
CRTX' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 1.5
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» CRTX's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Traded in other countries:DUJ1.Germany,

Cornerstone Therapeutics, Inc., a Delaware Corporation founded in 2000. The Company is a specialty pharmaceutical company which commercializes products for the hospital and adjacent specialty markets. Its currently marketed and approved products include: CARDENE I.V., an FDA-approved premixed injection indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable; CUROSURF, an FDA-approved natural lung surfactant indicated for the treatment of Respiratory Distress Syndrome, or RDS, in premature infants; ZYFLO, the only FDA-approved leukotriene synthesis inhibitor indicated for prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older; BETHKIS, an inhaled tobramycin-based product indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa, or PA, approved by the FDA in October 2012; Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended Release Suspension, or HP/CP ER Suspension, an FDA approved antitussive/antihistamine combination product that is a generic equivalent for the product currently sold under the Tussionex Pennkinetic,or Tussionex, brand name in the United States. Its customers consist of drug wholesalers, retail drug stores, mass merchandisers and grocery store pharmacies in the United States. It primarily sell products directly to drug wholesalers, which in turn distribute the products to retail drug stores, hospitals, mass merchandisers and grocery store pharmacies. It currently outsources the manufacturing of all of its commercially available products and the formulation development of its product candidates for use in clinical trials to third parties. It have U.S. and/or foreign trademark registrations and filings for certain of its corporate names, products (including CARDENE I.V., ZYFLO CR and ZYFLO) and product candidates (including RETAVASE and LIXAR). CUROSURF and BETHKIS are owned by Chiesi and are licensed to it for sales and marketing purposes in the United States. The Company faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions. The Company, its contract manufacturers and packagers, and its products and product candidates are subject to the Controlled Substances Act and DEA regulations thereunder.



Valuation & Return


More Statistics

Revenue (TTM) (Mil) $167.0
EPS (TTM) $ 0.33
Short Percentage of Float3.39%

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)